No, asymptomatic bacteriuria in otherwise healthy children should NOT be treated with antibiotics.
The 2019 IDSA guidelines provide a strong recommendation against screening for or treating asymptomatic bacteriuria (ASB) in healthy children, based on moderate-quality evidence showing no benefit and high-quality evidence of harm 1.
Key Evidence Against Treatment
No Clinical Benefit Demonstrated
Multiple randomized controlled trials in school-aged girls with ASB have consistently shown:
- No reduction in renal scarring between treated and untreated groups 1
- No differences in symptomatic UTI rates (pyelonephritis or cystitis occurred equally in both groups) 1
- No prevention of long-term complications such as renal insufficiency, impaired kidney growth, or resolution of vesicoureteral reflux 1
- Treatment only temporarily reduced ASB recurrence in the first 6 months, but showed no differences at 4 years 1
Evidence of Harm from Treatment
The guidelines emphasize high-quality evidence that antibiotics cause harm 1:
- Paradoxical increase in acute pyelonephritis: In one Swedish study, 6 out of 66 girls developed acute pyelonephritis within 5 months after receiving penicillin that eradicated their stable, long-term ASB 1. This suggests that disrupting stable bacterial colonization may actually increase risk of symptomatic infection.
- Antimicrobial resistance: Unnecessary treatment contributes to resistance patterns 1, 2
- Adverse drug effects and increased healthcare costs 1
- C. difficile infection risk 3
Clinical Context
Prevalence and Natural History
- ASB occurs in approximately 1-3% of healthy girls and is uncommon in infants and boys 1
- While bacteriuric children may have slightly increased risk of symptomatic UTI compared to non-bacteriuric children, this does not translate to increased renal scarring or renal insufficiency 1
- Many children with ASB remain bacteriuric long-term (47% in one cohort after 3 years) with normal renal growth and function 1
Important Caveats and Exceptions
Do NOT treat ASB in:
- Healthy preschool and school-aged children 1, 2
- Infants without symptoms 1, 2
- Children with diabetes 2, 3
- Children with spinal cord injuries 2
Special populations requiring further study: The guidelines acknowledge that children with neuromuscular disorders and immunocompromised states have not been adequately studied and represent a research priority 1. However, even in children with neurogenic bladder performing clean intermittent catheterization, current evidence does not support routine treatment of ASB 4.
The only pediatric exception would be children undergoing endourological procedures with expected mucosal trauma, where a single preoperative prophylactic dose may be reasonable 5, 2.
Common Pitfalls to Avoid
Do not confuse ASB with symptomatic UTI: Children with fever, dysuria, frequency, urgency, or systemic symptoms require evaluation and treatment—this is NOT asymptomatic bacteriuria 2, 6, 7
Do not screen for ASB: Screening 100,000 hypothetical preschool children would result in nearly 20,000 false-positive tests and cost approximately $2 million (1992 dollars) without clinical benefit 1
Resist pressure to "do something": The evidence clearly shows that treatment provides no benefit and may cause harm through disruption of stable colonization 1
Recognize that older studies still apply: While most ASB studies in children were conducted over 40 years ago, there are no indications that the incidence or outcomes would differ today 1
The recommendation is unequivocal: healthy children with asymptomatic bacteriuria should not receive antibiotic treatment, as this represents low-value care that poses risks without improving outcomes related to symptomatic infections, renal scarring, or long-term renal function 1, 2.